CTLA4 and melanoma: In the study by Wu and colleagues, a PYR-based model was constructed by analyzing RNA sequencing data and clinical information of melanoma patients from four immunotherapy databases, including Gide (patients receiving anti-PD1 or the combination anti-PD1 and anti-CTLA4), Lauss (patients treated with adoptive T-cell therapy), Liu (patients treated with anti-PD1) and Nathanson (patients treated with anti-CTLA4) [101].